Dr Dieter Scherer
AN INTEGRATED PIPELINE OF OPHTHALMIC PRODUCTS BASED ON EYESOL™ DELIVERY TECHNOLOGY
Dieter Scherer describes two of Novaliq’s most advanced products: NovaTears
, a wetting agent for the ocular surface, and CyclASol
, a clear formulation of Cyclosporin A. Both products use Novaliq’s semifluorinated alkane technology, EyeSol
Dr Ilva D Rupenthal
OCULAR DRUG DELIVERY TECHNOLOGIES: EXCITING TIMES AHEAD
Ilva Rupenthal gives a sector overview of the occular drug delivery space.
Dr Janice Cacace
EXCIPIENT SELECTION FOR OPHTHALMIC OINTMENTS
Janice Cacace and Travis Webb describe the physical properties of petrolatums as they relate to the comfort and efficacy of formulations of ophthalmic ointments.
COMPANY SHOWCASE: GRAYBUG
GrayBug is advancing ophthalmic therapeutics through a continuum of polymerbased drug delivery platforms and innovative products offering sustained competitive advantage.
Dr Daniel A Bernards
ZERO-ORDER SUSTAINED DRUG DELIVERY TO THE RETINA FROM A NANOPOROUS FILM DEVICE
Daniel Bernards, Robert Bhisitkul and Tejal Desai discuss the development of a nanoporous membrane-based implant which can significantly improve drug delivery to the back of the eye.
CURRENT AND FUTURE OPHTHALMIC FORMULATION AND PROCESS DEVELOPMENT TRENDS
Brian McMillan provides some insights into his personal experiences in the development of ophthalmic products and the significant role of innovative delivery systems in improving efficacy and reducing side-effects.
Dr Shikha P Barman
REVIEW OF PRESENT TECHNOLOGIES & STEPS FORWARD
Shikha Barman provides an overview of the current state of play in the ocular drug delivery market.
Dr Tomas Navratil
IMPROVING OUTCOMES IN OPHTHALMOLOGY VIA SUSTAINED DRUG DELIVERY
Tomas Navratil, Benjamin Maynor and Benjamin Yerxa describe the company’s particle engineering technology and its application in improving the delivery of prostaglandin analogues and anti-VEGF therapy.
REDUCE RISKS, MITIGATE FAILURE & DRIVE TIMELINES IN A COMPETITIVE MARKET
Badre Hammond, Shailuja Somaraju and Julie Suman highlight key considerations and present strategies to reduce risk and ultimately accelerate the process for gaining approval of an ophthalmic product, with a focus on the US.
Encompass Pharmaceutical Services
COMPANY PROFILE: ENCOMPASS
Encompass Pharma, based in Norcross, GA, US, was formed in 2004 by a highly experienced team of ophthalmic development and analytical scientists.
Micro Engineering Solutions
MICRO OPHTHALMIC OCULAR IMPLANTS
Donna Bibber explores one market segment in which micro manufacturing has played and will continue to play a significant role in worldwide growth in the next five years … ophthalmic devices.
Dr Robert Langer
BREAKTHROUGH NANOTECHNOLOGY ENHANCES DELIVERY TO THE FRONT AND BACK OF THE EYE
Hongming Chen and Robert Langer discuss applications of the company’s Mucus Penetrating Particle nanotechnology in ophthalmic drug delivery.
This website uses functional cookies (but not advertising cookies). View our
Privacy & Cookies Policy
W3 Total Cache is currently running in Pro version Development mode.